Halomine, Inc. Announces the Appointment of Dr. Xeuhong Ren as Chief Scientific Officer, Three New Board Members

ITHACA, N.Y.–(BUSINESS WIRE)–#HalomineHalomine™, Inc., a pioneer in advanced technology for managing surfaces and providing long-term protection against viruses, bacteria, and fungi, announced today the appointment of Dr. Xeuhong Ren as Chief Scientific Officer as well as 3 new members to their Board of Directors; Andy Gilicinski, Michael Aberman, and Alden Zecha.

Ted Eveleth, CEO of Halomine said “We are pleased to welcome Dr. Ren and our new board members. These appointments are important as we grow and bring new antimicrobial products to market, helping to make the world safer from dangerous pathogens. Dr. Ren is a distinguished world class scientist, and our new Board members bring a wealth of experience to our efforts.”

Dr. Xuehong Ren, one of the world’s leading authorities on synthesized monomers and polymers and n-Halomine chemistries, has joined Halomine Inc. as Chief Scientific Officer. Dr. Ren is the inventor of over twenty patents and the author of over 150 peer-reviewed journal articles. He earned his Textile Chemistry degree from Soochow University in China, and his PhD. in Polymer and Fiber Engineering from Auburn University.

Andy Gilicinski is a PhD Chemist and R&D Executive with 34 years of chemical and consumer products industry experience. He has cumulatively launched over $500MM in consumer products, and over the past 15 years also grew into a seasoned M&A veteran, leading nearly $2B in acquisitions. He is an inventor on 19 US patents and published over 20 peer-reviewed scientific papers. Andy earned his Chemistry degrees at the University of Illinois (BS) and University of Wisconsin – Madison (PhD). He currently also serves as Independent Director at Wyo-Ben, Inc. and on the Science Advisory Board at Sironix Renewables.

Michael Aberman, M.D. is a biotechnology executive with over 20 years of experience who is on the board or advising several early-stage biotechnology companies. Previously, he was the president and chief executive officer of Quentis Therapeutics, an early-stage biotech company. He received B.A. from Cornell University (’93), his medical degree from the University of Toronto (’97), completed residency training at New York Presbyterian Hospital, and received an M.B.A. from The Wharton School of Business (’01).

Alden Zecha is an international executive & board member merging social impact, technology & business to help leverage technology to drive greater profits while delivering positive social good. His executive experience spans operations and finance across several industries including technology, analytical instruments, financial services, logistics, and consumer products. He received his MSE and BSE with honors in chemical engineering from Princeton University and holds a certificate in finance from the University of Virginia’s Darden School of Business

Halomine’s other Board of Directors are CEO Ted Eveleth, CTO Mingyu Qiao, Dr. Minglin Ma, Cornell University, and Dr. Greg Bertsch, University of South Dakota.

Halomine™, Inc. is a chemistry-based technology and product company creating innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold, in a wide variety of applications. The company’s unique proprietary combinations of specialty molecules and polymers are customized to provide prolonged antimicrobial efficacy to a wide range of surfaces and materials. Halomine’s unique solutions can not only protect against pathogens for weeks or months, but also make surfaces easier to clean, resist adhesion, prevent fouling, and inhibit the formation of biofilms.


​Michael Newell, VP Sales and Marketing, Halomine Inc.

error: Content is protected !!